(Q38033590)

27 August 2017

title

Evolving therapeutic paradigms for multiple myeloma: back to the future (English)

1 reference

27 August 2017

1 reference

5

Ola Landgren

1 reference

27 August 2017

Benjamin M Cherry

1

1 reference

27 August 2017

Neha Korde

series ordinal

2

1 reference

27 August 2017

Mary Kwok

series ordinal

3

1 reference

27 August 2017

Mark Roschewski

series ordinal

4

1 reference

27 August 2017

language of work or name

1 reference

14 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

54

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

451-463

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

27 August 2017

1 reference

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

History of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Cancer chemotherapy--the first twenty-five years

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Cytokine therapeutics: lessons from interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Interferon-alpha in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Clinical toxicity of interferons in cancer patients: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Interferon-alpha as maintenance therapy in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

The treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Long-term follow-up after high-dose therapy for high-risk multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Lenalidomide--the phoenix rises.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Treatment options for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Lenalidomide mode of action: linking bench and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Second malignancies after multiple myeloma: from 1960s to 2010s

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Approach to the treatment of multiple myeloma: a clash of philosophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Lenalidomide in myeloma--a high-maintenance friend.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Cardiotoxicity of Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717277

10.3109/10428194.2012.717277

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference